Pay-related health care plans bring equity to cost sharing.
Explore the source record for details and available documents.
Cost Sharing↗
Biomedical subjects
K M Coughlin
Publications and source records attributed to K M Coughlin.
After 20 years, HMOs are still challenged to deliver quality.
Explore the source record for details and available documents.
Aged↗
While Congress debates, the states legislate.
Explore the source record for details and available documents.
Health Policy↗
Filling the gaps in stop-loss insurance.
Stop-loss insurance can provide protection from catastrophic medical claims for self-insured companies: But buyer beware.
Commerce↗
Expanding employee assistance programs is paying dividends.
Explore the source record for details and available documents.
Cost Savings↗
Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B.
Carboplatin (400 mg/m2) was given at 28-day intervals to 41 patients with malignant mesothelioma. In all, 40 patients were eligible and evaluable for response. Partial responses were seen in 2 cases (5%); regression of evaluable disease, in 1 patient (2%); and stable disease, in 19 subjects (48%). A median of two doses of carboplatin per patient resulted in mild toxicity. Leukopenia (less than or equal to 2,000 cells/microliters) and thrombocytopenia (less than 100,000 cells/microliters) were seen in only 6% and 20% of the patients, respectively. Median survival from study entry was estimated at 7.1 months, with a 1-year survival of 25% +/- 7%. Carboplatin given at a dose of 400 mg/m2 at 28-day intervals shows minor activity against malignant mesothelioma.
Adult↗